|
Recent updates and publications
Alpharadin and Skeletal Metastases - A Phase III Trial
A direct link to the ongoing phase III trial, that recently was activated in US centers, directs you to the NIH/NCI clinical trials web page - click here.
Review of the clinical development of Radium 223 - Alpharadin.
Chapter 10 in a recent textbook on targeted radionuclide tumour therapy by Springer Verlag, 2008. Click here to open the chapter in PDF format.
Normal tissue toxicity of radiotherapy
In December, 2007, we published a paper in Acta Oncologica on: Radiological and functional assessment of radiation-induced pulmonary damage following breast irradiation. Click here for PDF of the paper.
[11.01.08 15:01]
Radiotherapy of soft tissue sarcoma
A paper from our group by Nina L. Jebsen et al. was recently accepted and is currently in press for Int. Journal of Radiation Oncology, Biology, Physics. Ref.: No. ROB-D-07-01341R1 Radiotherapy improves local control regardless of surgical margin and malignancy grade in extremity and trunk wall soft tissue sarcoma. A Scandinavian Sarcoma Group Study of 1093 patients. International Journal of Radiation Oncology, Biology,Physics Click here for a pdf of the publication
[20.11.07 12:27]
Den gies ut av forlaget Fri Flyt i anledning Norsk Tindeklub's 100-års jubileum. Førstehjelp på tur Fjell-, høyde- og reisemedisin (klikk for å åpne bokomtale i Word-format) Les anmeldelsen av boken i Tidsskrift for Den Norske Lægeforening ved å klikke her (PDF)
Publication in "Lung Cancer":
Porojnicu AC, Robsahm TE, Dahlback A, Berg JP, Christiani D, Bruland OS, Moan J. (2007 Mar) Seasonal and geographical variations in lung cancer prognosis in Norway Does Vitamin D from the sun play a role? Lung Cancer 55(3):263-70 View a pdf of the paper by clicking here
Fast track - Int. J. Cancer: 120, 1603–1609 (2007)
Treatment of bone metastasis
[26.10.06 12:10]
ASCO - Prostate Cancer Symposium, San Fransisco
First results from the completed phase 2 study were presented at ASCO - Prostate Cancer Symposium, San Fransisco 23-26/2-06. Click here to view abstract of presentation and poster
Ny kreftbehandling
Det norske selskapet Algeta ASA vekker internasjonale investorers interesse. Selskapet får 185 millioner kroner fra tunge venturefond for å videreutvikle en ny type behandling for prostatakreft som har spredd seg til skjelett. Last ned artikkel fra Dagens Næringsliv (PDF-format) Bildet til høyre: Dr. philos Roy H. Larsen var Brulands første stipendiat, og de stiftet selskapet i 1997.
|
|
|
Print this page